KR100827942B1 - 항종양제로서의 3-하이드록시-2-(하이드록시메틸)-2-메틸프로피온산과의 라파마이신 42-에스테르(cci-779)를 포함하는 약제학적 조성물 - Google Patents
항종양제로서의 3-하이드록시-2-(하이드록시메틸)-2-메틸프로피온산과의 라파마이신 42-에스테르(cci-779)를 포함하는 약제학적 조성물 Download PDFInfo
- Publication number
- KR100827942B1 KR100827942B1 KR1020037006542A KR20037006542A KR100827942B1 KR 100827942 B1 KR100827942 B1 KR 100827942B1 KR 1020037006542 A KR1020037006542 A KR 1020037006542A KR 20037006542 A KR20037006542 A KR 20037006542A KR 100827942 B1 KR100827942 B1 KR 100827942B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- tumor
- pharmaceutical composition
- cci
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
신장 종양주 | CCI-779 IC50(nM) |
HTB-44 | 5.0 |
CRL-1161 | 2.0 |
SN12-C | 5.5 |
세포주 | 약제 치료 | 종양 질량(mg) | |||||
일 | |||||||
0 | 7 | 21 | 35 | 49 | 55 | ||
HTB-44 | 대조군 CCI % T/C | 288±21 290±15 101 | 219±18 156±13* 71 | 616±55 252±48* 41 | 1095±44 453±85* 41 | 2033±247 980±155* 48 | 2412±342 1050±183* 44 |
CRL-1161 | 대조군 CCI % T/C | 273±18 272±14 100 | 355±36 219±16* 62 | 413±60 226±17* 60 | 480±127 200±21* 42 | 546±170 229±28* 42 | 507±156 268±30 53 |
* p 값 - <.05 % T/C - 치료군/대조군 ×100 |
Claims (21)
- 유효량의 3-하이드록시-2-(하이드록시메틸)-2-메틸프로피온산과의 라파마이신 42-에스테르(CCI-779)를 포함하는, 연조직육종, 폐의 신경내분비 종양, 자궁경부암, 자궁암, 두경부암, 비소세포폐암, 림프종, 소세포폐암, 난소암 및 결장암으로부터 선택된 종양 치료용 약제학적 조성물.
- 유효량의 3-하이드록시-2-(하이드록시메틸)-2-메틸프로피온산과의 라파마이신 42-에스테르(CCI-779)를 포함하는, 연조직육종, 유방암, 폐의 신경내분비 종양, 자궁경부암, 자궁암, 두경부암, 아교모세포종, 비소세포폐암, 전립선암, 췌장암, 림프종, 흑색종, 소세포폐암, 난소암 및 결장암으로부터 선택된 난치성 종양 치료용 약제학적 조성물.
- 삭제
- 제1항 또는 제2항에 있어서, 종양이 연조직육종인 약제학적 조성물.
- 제2항에 있어서, 종양이 유방암인 약제학적 조성물.
- 제1항 또는 제2항에 있어서, 종양이 폐의 신경내분비 종양인 약제학적 조성물.
- 제1항 또는 제2항에 있어서, 종양이 자궁경부암인 약제학적 조성물.
- 제1항 또는 제2항에 있어서, 종양이 자궁암인 약제학적 조성물.
- 제1항 또는 제2항에 있어서, 종양이 두경부암인 약제학적 조성물.
- 제2항에 있어서, 종양이 아교모세포종인 약제학적 조성물.
- 제1항 또는 제2항에 있어서, 종양이 비소세포폐암인 약제학적 조성물.
- 제2항에 있어서, 종양이 전립선암인 약제학적 조성물.
- 제2항에 있어서, 종양이 췌장암인 약제학적 조성물.
- 제1항 또는 제2항에 있어서, 종양이 림프종인 약제학적 조성물.
- 제2항에 있어서, 종양이 흑색종인 약제학적 조성물.
- 제1항 또는 제2항에 있어서, 종양이 소세포폐암인 약제학적 조성물.
- 제1항 또는 제2항에 있어서, 종양이 난소암인 약제학적 조성물.
- 제1항 또는 제2항에 있어서, 종양이 결장암인 약제학적 조성물.
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24907700P | 2000-11-15 | 2000-11-15 | |
US60/249,077 | 2000-11-15 | ||
PCT/US2001/047324 WO2002040000A2 (en) | 2000-11-15 | 2001-11-13 | Use of cci-779 as an antineoplastic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040029309A KR20040029309A (ko) | 2004-04-06 |
KR100827942B1 true KR100827942B1 (ko) | 2008-05-13 |
Family
ID=22941961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037006542A KR100827942B1 (ko) | 2000-11-15 | 2001-11-13 | 항종양제로서의 3-하이드록시-2-(하이드록시메틸)-2-메틸프로피온산과의 라파마이신 42-에스테르(cci-779)를 포함하는 약제학적 조성물 |
Country Status (28)
Country | Link |
---|---|
US (3) | US20020091137A1 (ko) |
EP (1) | EP1335725B1 (ko) |
JP (4) | JP4472251B2 (ko) |
KR (1) | KR100827942B1 (ko) |
CN (2) | CN1678312A (ko) |
AR (1) | AR031341A1 (ko) |
AT (1) | ATE393629T1 (ko) |
AU (2) | AU2731302A (ko) |
BR (1) | BR0115323A (ko) |
CA (1) | CA2429020C (ko) |
CY (1) | CY1108109T1 (ko) |
DE (1) | DE60133831T2 (ko) |
DK (1) | DK1335725T3 (ko) |
EA (1) | EA007096B1 (ko) |
ES (1) | ES2305134T3 (ko) |
HK (1) | HK1058008A1 (ko) |
HU (1) | HUP0400521A3 (ko) |
IL (2) | IL155871A0 (ko) |
MX (1) | MXPA03004192A (ko) |
NO (1) | NO20032181L (ko) |
NZ (1) | NZ539668A (ko) |
PL (1) | PL207061B1 (ko) |
PT (1) | PT1335725E (ko) |
SG (1) | SG148031A1 (ko) |
SI (1) | SI1335725T1 (ko) |
TW (1) | TWI286074B (ko) |
WO (1) | WO2002040000A2 (ko) |
ZA (1) | ZA200304603B (ko) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
AU2002250968C1 (en) | 2001-02-19 | 2018-01-04 | Novartis Ag | Cancer treatment |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
NZ529877A (en) * | 2001-06-01 | 2006-08-31 | Wyeth Corp | Antineoplastic combinations |
ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
ES2485841T3 (es) * | 2002-02-01 | 2014-08-14 | Ariad Pharmaceuticals, Inc | Compuestos que contienen fósforo y usos de los mismos |
AU2003280437A1 (en) * | 2002-06-27 | 2004-01-19 | Microport Medical (Shanghai) Co., Ltd. | Drug eluting stent |
UA82328C2 (uk) | 2002-07-30 | 2008-04-10 | Уайт | Парентеральна композиція на основі гідроксіестеру рапаміцину (варіанти) та спосіб її приготування |
RU2326654C2 (ru) * | 2002-09-17 | 2008-06-20 | Уайт | Пероральные композиции |
WO2004048933A2 (en) | 2002-11-21 | 2004-06-10 | Wyeth | Methods for diagnosing rcc and other solid tumors |
US7643943B2 (en) | 2003-02-11 | 2010-01-05 | Wyeth Llc | Methods for monitoring drug activities in vivo |
US20050287532A9 (en) * | 2003-02-11 | 2005-12-29 | Burczynski Michael E | Methods for monitoring drug activities in vivo |
CA2515677A1 (en) * | 2003-02-11 | 2004-08-26 | Wyeth | Methods for monitoring drug activities in vivo |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
UA80756C2 (en) * | 2003-04-22 | 2007-10-25 | Wyeth Corp | Antineoplastic combinations of rapomicine and interferon alfa (?) in the treatment of neoplasms |
EP1618218A2 (en) * | 2003-04-29 | 2006-01-25 | Wyeth | Methods for prognosis and treatment of solid tumors |
WO2005011688A1 (en) * | 2003-07-25 | 2005-02-10 | Wyeth | Cci-779 lyophilized formulations |
AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
MXPA06007829A (es) * | 2004-01-08 | 2006-09-01 | Wyeth Corp | Composicion farmaceutica directamente comprimible para la administracion oral de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico. |
AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
CN113975393A (zh) | 2005-02-03 | 2022-01-28 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
JP2008530145A (ja) * | 2005-02-15 | 2008-08-07 | ワイス | 経口投与可能なcci−779製剤 |
US20070104721A1 (en) | 2005-11-04 | 2007-05-10 | Wyeth | Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272 |
US9006224B2 (en) * | 2005-11-21 | 2015-04-14 | Novartis Ag | Neuroendocrine tumor treatment |
AU2006331874A1 (en) * | 2005-12-20 | 2007-07-05 | Wyeth | Control of CCI-779 dosage form stability through control of drug substance impurities |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
US20090076060A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched temsirolimus |
CA2709413C (en) * | 2007-10-03 | 2017-09-12 | Genesis Technical Systems Corp. | Dynamic, asymmetric rings |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
JP5647098B2 (ja) | 2008-03-21 | 2014-12-24 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド拮抗薬とmTOR阻害薬を用いた治療 |
AU2013205002B2 (en) * | 2008-03-21 | 2016-09-15 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
WO2010008744A2 (en) | 2008-06-17 | 2010-01-21 | Wyeth | Antineoplastic combinations containing hki-272 and vinorelbine |
MX2011001318A (es) | 2008-08-04 | 2011-03-04 | Wyeth Llc | Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina. |
RU2011139363A (ru) | 2009-04-06 | 2013-05-20 | ВАЙЕТ ЭлЭлСи | Схема лечения рака молочной железы с использованием нератиниба |
US8716307B2 (en) * | 2009-05-13 | 2014-05-06 | The Trustees Of The University Of Pennsylvania | Combination antineoplastic therapy |
WO2011151704A2 (en) * | 2010-06-02 | 2011-12-08 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of rapamycin esters |
US9745941B2 (en) * | 2014-04-29 | 2017-08-29 | Ford Global Technologies, Llc | Tunable starter resistor |
CA2992629C (en) * | 2015-08-24 | 2020-06-30 | Shanxi Yabao Health Products Co., Ltd. | Use of dihydroxyacetone in preparation of anti-cancer medicaments |
CN111110676A (zh) * | 2020-03-07 | 2020-05-08 | 天津医科大学总医院 | 阿帕替尼及联合cci-779在制备肺癌药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
US5078999A (en) | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
EP0525960B1 (en) | 1991-06-18 | 1996-03-20 | American Home Products Corporation | Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma |
ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
ES2228932T3 (es) | 2000-08-11 | 2005-04-16 | Wyeth | Procedimiento de tratamiento del carcinoma positivo de estrogenos. |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
-
2001
- 2001-11-05 TW TW090127415A patent/TWI286074B/zh not_active IP Right Cessation
- 2001-11-13 ES ES01996175T patent/ES2305134T3/es not_active Expired - Lifetime
- 2001-11-13 US US10/010,584 patent/US20020091137A1/en not_active Abandoned
- 2001-11-13 BR BR0115323-4A patent/BR0115323A/pt not_active Application Discontinuation
- 2001-11-13 CA CA002429020A patent/CA2429020C/en not_active Expired - Lifetime
- 2001-11-13 MX MXPA03004192A patent/MXPA03004192A/es active IP Right Grant
- 2001-11-13 SI SI200130829T patent/SI1335725T1/sl unknown
- 2001-11-13 HU HU0400521A patent/HUP0400521A3/hu unknown
- 2001-11-13 AT AT01996175T patent/ATE393629T1/de not_active IP Right Cessation
- 2001-11-13 DK DK01996175T patent/DK1335725T3/da active
- 2001-11-13 EP EP01996175A patent/EP1335725B1/en not_active Expired - Lifetime
- 2001-11-13 CN CNA018189261A patent/CN1678312A/zh active Pending
- 2001-11-13 NZ NZ539668A patent/NZ539668A/en unknown
- 2001-11-13 KR KR1020037006542A patent/KR100827942B1/ko active IP Right Grant
- 2001-11-13 AU AU2731302A patent/AU2731302A/xx active Pending
- 2001-11-13 DE DE60133831T patent/DE60133831T2/de not_active Expired - Lifetime
- 2001-11-13 EA EA200300566A patent/EA007096B1/ru not_active IP Right Cessation
- 2001-11-13 IL IL15587101A patent/IL155871A0/xx unknown
- 2001-11-13 PL PL362740A patent/PL207061B1/pl unknown
- 2001-11-13 JP JP2002542375A patent/JP4472251B2/ja not_active Expired - Lifetime
- 2001-11-13 PT PT01996175T patent/PT1335725E/pt unknown
- 2001-11-13 WO PCT/US2001/047324 patent/WO2002040000A2/en active IP Right Grant
- 2001-11-13 CN CN2010101653331A patent/CN102058588A/zh active Pending
- 2001-11-13 SG SG200505237-8A patent/SG148031A1/en unknown
- 2001-11-14 AR ARP010105310A patent/AR031341A1/es unknown
-
2003
- 2003-02-26 US US10/374,644 patent/US7189735B2/en not_active Expired - Lifetime
- 2003-05-12 IL IL155871A patent/IL155871A/en active IP Right Grant
- 2003-05-14 NO NO20032181A patent/NO20032181L/no not_active Application Discontinuation
- 2003-06-12 ZA ZA200304603A patent/ZA200304603B/en unknown
-
2004
- 2004-02-10 HK HK04100881A patent/HK1058008A1/xx not_active IP Right Cessation
-
2007
- 2007-02-01 US US11/701,109 patent/US7781446B2/en not_active Expired - Fee Related
- 2007-03-27 AU AU2007201324A patent/AU2007201324B2/en not_active Expired
-
2008
- 2008-06-02 CY CY20081100573T patent/CY1108109T1/el unknown
-
2009
- 2009-09-18 JP JP2009216883A patent/JP2010018620A/ja active Pending
-
2014
- 2014-01-15 JP JP2014005231A patent/JP2014088430A/ja not_active Withdrawn
-
2015
- 2015-12-10 JP JP2015241449A patent/JP2016094444A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100827942B1 (ko) | 항종양제로서의 3-하이드록시-2-(하이드록시메틸)-2-메틸프로피온산과의 라파마이신 42-에스테르(cci-779)를 포함하는 약제학적 조성물 | |
US20060030547A1 (en) | Antineoplastic combinations | |
JP2006519862A (ja) | 抗腫瘍剤の組み合わせ | |
AU2008202690A1 (en) | Antineoplastic combination | |
AU2002330994A1 (en) | Antineoplastic combinations | |
PT1615640E (pt) | Combinações antineoplásticas | |
AU2002259309A1 (en) | Antineoplastic combinations | |
KR101544222B1 (ko) | 유두상 신세포암에서의 템시로리무스의 항종양 활성 | |
KR101387988B1 (ko) | 맨틀 세포 림프종 치료용 cci-779 | |
AU2002227313B2 (en) | Use of CCI-779 as an antineoplastic agent | |
AU2002227313A1 (en) | Use of CCI-779 as an antineoplastic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120329 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130329 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160330 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170330 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180329 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190327 Year of fee payment: 12 |